Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Stock Has Consensus Price Target of $15.86

Key Points

• Analysts remain broadly bullish: Inventiva has a consensus “Buy” rating from 10 analysts—seven buys, two strong buys and one sell—with an average 12-month price target of $15.86.
• Inventiva shares opened at $3.71, well below the consensus target, and remain near the lower end of their 52-week range of $2.82 to $7.98. Recent analysts including Guggenheim and Truist Financial raised their price targets to $14 and $18, respectively.
• The clinical-stage biopharmaceutical company is developing lanifibranor, its lead oral drug candidate for MASH, which is being evaluated in the Phase 3 NATiV3 trial. Inventiva reported quarterly revenue of $0.75 million and a loss of $0.14 per share.

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) have been assigned an average rating of "Buy" from the ten analysts that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, seven have issued a buy rating and two have given a strong buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $15.86.

A number of equities research analysts have recently commented on the company. Cantor Fitzgerald assumed coverage on Inventiva in a research report on Friday, July 17th. They set an "overweight" rating on the stock. Weiss Ratings raised Inventiva from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday. Piper Sandler reiterated an "overweight" rating on shares of Inventiva in a research report on Wednesday, September 16th. Guggenheim raised their price objective on Inventiva from $11.00 to $14.00 and gave the company a "buy" rating in a report on Tuesday, September 15th. Finally, Truist Financial boosted their price objective on Inventiva from $13.00 to $18.00 and gave the company a "buy" rating in a research report on Friday, October 2nd.

Institutional Investors Weigh In On Inventiva

A number of institutional investors have recently added to or reduced their stakes in the stock. Seven Fleet Capital Management LP purchased a new stake in Inventiva in the 1st quarter worth $1,111,000. Engineers Gate Manager LP lifted its holdings in Inventiva by 155.5% during the second quarter. Engineers Gate Manager LP now owns 71,116 shares of the company's stock valued at $269,000 after purchasing an additional 43,280 shares in the last quarter. Finally, Platt Investment Counsel LLC purchased a new position in Inventiva during the third quarter valued at $45,000. Institutional investors and hedge funds own 19.06% of the company's stock.

Inventiva Price Performance

NASDAQ:IVA opened at $3.71 on Monday. The company has a 50 day moving average price of $3.92 and a 200-day moving average price of $4.39. Inventiva has a 1-year low of $2.82 and a 1-year high of $7.98.

Inventiva (NASDAQ:IVA - Get Free Report) last posted its earnings results on Friday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter. The company had revenue of $0.75 million for the quarter. Analysts forecast that Inventiva will post -0.79 EPS for the current fiscal year.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva's lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.